RT Journal Article
T1 Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group.
A1 Provencio, Mariano
A1 Royuela, Ana
A1 Torrente, María
A1 Pollán, Marina
A1 Gómez-Codina, José
A1 Sabín, Pilar
A1 Llanos, Marta
A1 Gumá, Josep
A1 Quero, Cristina
A1 Blasco, Ana
A1 Aguiar, David
A1 García-Arroyo, Francisco Ramón
A1 Lavernia, Javier
A1 Martínez, Natividad
A1 Morales, Manuel
A1 Saenz-Cusi, Álvaro
A1 Rodríguez, Delvys
A1 Calvo, Virginia
A1 de la Cruz-Merino, Luis
A1 de la Cruz, Miguel Ángel
A1 Rueda, Antonio
A1 Spanish Lymphoma Oncology Group, 
K1 follicular lymphoma
K1 mortality
K1 standard mortality ratio
AB Relatively few studies have analyzed the mortality of follicular lymphoma (FL) patients in comparison with a sex- and age-matched general population. This study analyzed the overall survival (OS) of patients with FL and compared their survival with the expected survival of a general population. Patients diagnosed with FL were prospectively enrolled from 1980 to 2013. Standardized mortality ratios (SMRs) were obtained from yearly sex- and age-specific mortality rates in Spain, and OS was compared with age- and sex-matched general population data. A total of 1074 patients with newly diagnosed FL were enrolled. The median OS was 231 months (95% confidence interval [CI], 195-267 months). Event-free survival at 12 months (EFS12) and event-free survival at 24 months (EFS24) were associated with an increased probability of early death, with an SMR of 10.27 (95% CI, 8.26-12.77) for EFS12. The overall SMR, including all causes of death, was 2.55 (95% CI, 2.23-2.92), and it was higher for women (SMR, 3.02; 95% CI, 2.48-3.67) and young adults (SMR, 6.01; 95% CI, 3.13-11.55). More than 10 years after the diagnosis, mortality rates for FL patients were lower than those for the general population (SMR, 0.47; 95% CI, 0.28-0.78). When FL was excluded as a cause of death, the overall SMR was 1.35 (95% CI, 1.11-1.65) without a statistically significant mortality increase in the >60-year-old group in comparison with age- and sex-matched general population data. More than 15% of the patients included in the study (n = 158) had more than 10 years of follow-up. EFS12 and EFS24 predict an early increase in mortality. The long-term SMR, over the course of 10 years of follow-up, shows that patients with FL have a risk of dying similar to that of a sex- and age-matched general population. Cancer 2017;123:3709-3716. © 2017 American Cancer Society.
YR 2017
FD 2017-06-13
LK http://hdl.handle.net/10668/11297
UL http://hdl.handle.net/10668/11297
LA en
DS RISalud
RD Apr 18, 2025